On November 21st at 8 AM New York time a select group of investors from America, Europe, Asia and the Middle East will gather on a group-video-call.

After the opening exchange of insights, participants will take part in a deep dive into TRISYNTEC, which is redesigning the functionality and purpose of a predictive artificial intelligence (AI) with a data-driven, digitally focused NMMI pulmonary disease diagnostic technology in collaboration with a noninvasive, de novo wearable therapeutic medical device having derivative respiratory disease applications for TB, COPD, and Sleepapnea.

Prior clinical trials have demonstrated a 40% breathing enhancement for device users.  Worn twice daily, the at-home therapy is battery operated.

Our goal for this event is to secure over $10 million in total commitments, while allowing flexibility for participants to invest at different levels.

The agenda of the gathering:

• An interactive round table
• A live presentation of TRISYNTEC: its technology, traction, and growth strategy
• A co-development session where investors contribute strategic input and explore synergies with the founding team
• A final round of one-to-one meetings between investors and TRISYNTEC, as well as with each other, enabling direct follow-ups and alignment

Held via video group call on November 21st, 2025, the session runs for 3 hours
(5-8 pm Dubai time, and 8-11 am New York time).